Incyte announced positive topline results from its two pivotal Phase 3 trials, TRuE-V1 and TRuE-V2, evaluating the safety and efficacy of ruxolitinib cream in adolescent…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.